<DOC>
	<DOCNO>NCT00241020</DOCNO>
	<brief_summary>Hepatocellular carcinoma ( HCC ) one common malignant disease worldwide increase incidence industrialized country . For patient advanced HCC efficient treatment currently available . The objective study ass efficacy safety octreotide patient advanced hepatocellular carcinoma .</brief_summary>
	<brief_title>Evaluation Efficacy Long-acting Release Octreotide Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>&gt; 18 year HCC diagnosis : histologically cytologically proven HCC association three follow criterion : cirrhosis typical measurable mass ( &gt; 3cm , 2 method ) serum alphafoetoprotein ( AFP ) ≥500 µg/L Cancer Liver Italian Program ( CLIP ) score : 0 3 Not eligible specific treatment ( surgery , percutaneous ablation chemoembolization ) Glycemia &gt; 2.5 g/L hypoglycemia Extra hepatic lifethreatening disease Serum creatinin &gt; 120 µmol/L Prothrombin time &lt; 50 % Platelet count &lt; 50.000 /µL Symptomatic cholelithiasis Nonmeasurable tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>Octreotide</keyword>
</DOC>